Skip to main content

Advertisement

SpringerLink
Log in

Longitudinal monitor of Jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients

  • Original Article
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Objective

This study aimed to investigate the correlation of Jun N-terminal kinase pathway associated phosphatase (JKAP) with inflammation, disease activity, and clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs (cDMARDs) in rheumatoid arthritis (RA) patients.

Methods

A total of 119 active RA patients about to receive triple cDMARDs treatment were enrolled. Serum JKAP was detected by enzyme-linked immunosorbent assay at week0, week6, week12, and week24 (W24). According to clinical response status or remission status at W24, RA patients were classified as response patients and non-response patients, or remission patients and non-remission patients, respectively.

Results

JKAP was negatively correlated with erythrocyte sedimentation rate (ESR), C-reactive protein, and 28-joints disease activity score based on ESR (DAS28 score (ESR)), while JKAP was not correlated with disease duration, tender joint count, swollen joint count, health assessment questionnaire for rheumatoid arthritis or treatment history. Furthermore, during 24-week triple cDMARDs treatment, JKAP was increased overtime. Subgroup analyses showed that JKAP displayed a rising trend in response patients, remission patients, non-remission patients but not non-response patients, meanwhile its increment was more obvious in remission patients versus non-remission patients. Additionally, JKAP at W24 was higher in response patients compared with non-response patients, and JKAP at W12 and W24 was higher in remission patients compared with non-remission patients.

Conclusion

Longitudinal monitor of JKAP might reflect clinical efficacy to the treatment of triple cDMARDs, which could improve outcomes in RA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320:1360–1372

    Article  Google Scholar 

  • Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581

    Article  Google Scholar 

  • Allen A, Carville S, McKenna F, Guideline Development G (2018) Diagnosis and management of rheumatoid arthritis in adults: summary of updated NICE guidance. BMJ 362:k3015

    Article  Google Scholar 

  • Chen AJ, Zhou G, Juan T, Colicos SM, Cannon JP, Cabriera-Hansen M, Meyer CF, Jurecic R, Copeland NG, Gilbert DJ, Jenkins NA, Fletcher F, Tan TH, Belmont JW (2002) The dual specificity JKAP specifically activates the c-Jun N-terminal kinase pathway. J Biol Chem 277:36592–36601

    Article  CAS  Google Scholar 

  • Chuang HC, Chen YM, Hung WT, Li JP, Chen DY, Lan JL, Tan TH (2016) Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis. Oncotarget 7:57593–57605

    Article  Google Scholar 

  • Hu H, Luan L, Yang K, Li SC (2018) Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China. Int J Rheum Dis 21:1572–1580

    Article  Google Scholar 

  • Li JP, Yang CY, Chuang HC, Lan JL, Chen DY, Chen YM, Wang X, Chen AJ, Belmont JW, Tan TH (2014) The phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck. Nat Commun 5:3618

    Article  Google Scholar 

  • Ma K, Li L, Liu C, Zhou L, Zhou X (2019) Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis. Arch Med Sci 15:33–54

    Article  CAS  Google Scholar 

  • Shi X, Yang W, Wang N, Zhu J (2019) Circulating JNK pathway-associated phosphatase level correlates with decreased risk, activity, inflammation level and reduced clinical response to tumor necrosis factor-alpha inhibitor in Crohn disease patients. Medicine (Baltimore) 98:e16622

    Article  CAS  Google Scholar 

  • Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023–2038

    Article  CAS  Google Scholar 

  • Sparks JA (2019) Rheumatoid Arthritis. Ann Intern Med 170:ITC1–ITC16

    Article  Google Scholar 

  • van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB & van Riel PL (1996) Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American college of rheumatology and the world health organization/International league against rheumatism criteria. Arthritis Rheum 39: 34–40

  • Zhou R, Chang Y, Liu J, Chen M, Wang H, Huang M, Liu S, Wang X, Zhao Q (2017) JNK Pathway-associated phosphatase/DUSP22 suppresses CD4(+) T-Cell activation and Th1/Th17-cell differentiation and negatively correlates with clinical activity in inflammatory bowel disease. Front Immunol 8:781

    Article  Google Scholar 

Download references

Acknowledgements

None.

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, Affiliated Hospital of Jiangnan University, No. 200 Huihe Road, Binhu District, Wuxi, 214062, China

    Dongming Song, Xiaoxia Zhu, Fangming Wang & Jian Sun

Authors
  1. Dongming Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoxia Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fangming Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian Sun.

Ethics declarations

Conflicts of interest

All authors declare that there is no conflict of interest.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, D., Zhu, X., Wang, F. et al. Longitudinal monitor of Jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients. Inflammopharmacol 29, 1131–1138 (2021). https://doi.org/10.1007/s10787-021-00823-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-021-00823-w

Keywords

Search

Navigation